Patents Examined by Janet L Coppins
  • Patent number: 9808457
    Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: November 7, 2017
    Assignee: Heptares Therapeutics Limited
    Inventors: John Andrew Christopher, Miles Stuart Congreve, Sarah Joanne Bucknell, Francesca Deflorian, Mark Pickworth, Jonathan Stephen Mason
  • Patent number: 9801884
    Abstract: Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 31, 2017
    Assignee: The Regents of the University of California
    Inventors: Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
  • Patent number: 9801866
    Abstract: Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: October 31, 2017
    Assignee: Rigl Pharmaceutical, Inc.
    Inventors: Matthew Duncton, Somasekhar Bhamidipati, Jiaxin Yu, Ihab Darwish, Rajinder Singh
  • Patent number: 9801856
    Abstract: The present invention relates to certain compositions of a 5-HT2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improvise sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: October 31, 2017
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Lee Alani Selvey, Marlon Carlos, Paul Maffuid, Yun Shan, William L. Betts, III, Deam Windate Given, III, Ryan M. Hart, Zezhi Jesse Shao
  • Patent number: 9782368
    Abstract: According to the invention there is provided N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, for use in regenerating ascorbate systemically and thus in the therapeutic treatment of chronic obstructive pulmonary disease.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: October 10, 2017
    Assignee: Emeramed Limited
    Inventors: Boyd Eugene Haley, Ragnar Axel Theodor Klingberg
  • Patent number: 9782360
    Abstract: The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: October 10, 2017
    Assignees: UNIVERSIDADE DE SAO PAULO—USP, UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL—UFRGS, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
    Inventors: Raphael Mechoulam, Antonio Waldo Zuardi, Flavio Pereira Kapczinski, Jaime Eduardo Cecilio Hallak, Francisco Silveira Guimaraes, Jose Alexandre de Souza Crippa, Aviva Breuer
  • Patent number: 9770025
    Abstract: The present invention relates to novel fungicidal compositions for the treatment of phytopathogenic diseases of useful plants, especially phytopathogenic fungi, and to a method of controlling such phytopathogenic diseases on useful plants. In particular compositions suitable for control of diseases caused by phytopathogens comprise a mixture of a compound of formula (I), with a compound selected from compounds known for their fungicidal activity; and a method of controlling diseases on useful plants using such compositions.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: September 26, 2017
    Assignee: Syngenta Participations AG
    Inventors: Gina Mercia Swart, Michael Oostendorp
  • Patent number: 9763915
    Abstract: The present invention provides a 1,2,4-trioxane or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof for use as an adjuvant for a tyrosine kinase inhibitor to enhance the activity of said tyrosine kinase inhibitor in a method for the treatment of a patient suffering from cancer, a pharmaceutical composition comprising a tyrosine kinase inhibitor as an active ingredient and said 1,2,4-trioxane adjuvant or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof in an amount sufficient to enhance the activity of the tyrosine kinase inhibitor, preferably for use in a method for the treatment of cancer.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: September 19, 2017
    Assignee: PharmOxaco SáRL
    Inventors: Charles William Jefford, Daniel Hoessli
  • Patent number: 9757373
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: September 12, 2017
    Assignee: SynDevRx, Inc.
    Inventors: John S. Petersen, James Shanahan
  • Patent number: 9750737
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: September 5, 2017
    Assignee: SynDevRx, Inc.
    Inventors: John S. Petersen, James Shanahan
  • Patent number: 9745270
    Abstract: The present invention is directed to processes and intermediates useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea (Compound I), crystalline forms and solvate forms thereof; and compositions comprising 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea, crystalline forms and solvate forms thereof prepared by processes as described herein.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: August 29, 2017
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Marlon Carlos, Weitong Dong, Mark Macias, Suzanne Michiko Sato, Lee Alani Selvey
  • Patent number: 9744154
    Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: August 29, 2017
    Assignee: SIGA TECHNOLOGIES, INC.
    Inventors: Shanthakumar R. Tyavanagimatt, Melialani A.C.L.S. Anderson, William C. Weimers, Dylan Nelson, Tove′ C. Bolken, Dennis E. Hruby, Michael H. O'Neill, Gary Sweetapple, Kelley A. McCloughan
  • Patent number: 9737512
    Abstract: Certain embodiments are directed to methods of treating pain, e.g., chronic or neuropathic pain, comprising administering an effective amount of an EPAC inhibitor.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: August 22, 2017
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Xiaodong Cheng, Fang Mei, Annemieke Kavelaars, Cobi J. Heijnen
  • Patent number: 9737510
    Abstract: The patent discloses novel indazole compounds of general formula 1 and analogues thereof, use thereof for the treatment of diabetes, diabetic complications, cardiovascular dysfuntion or related diseases, pharmaceutical compositions comprising them and processes for their preparation.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: August 22, 2017
    Assignees: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH, SHANTANI PROTEOME ANALYTICS PVT. LTD
    Inventors: Dumbala Srinivasa Reddy, Chaitanya Saxena, Kashinath Komirishetty
  • Patent number: 9730931
    Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: August 15, 2017
    Assignee: EISAI R&D Management Co., Ltd.
    Inventors: Dominic Reynolds, Ming-Hong Hao, John Wang, Sudeep Prajapati, Takashi Satoh, Anand Selvaraj
  • Patent number: 9724328
    Abstract: Treating subjects having a lipid storage disorder with a composition comprising a PKC activator, such as bryostatins, bryologs, and polyunsaturated fatty acids.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: August 8, 2017
    Assignees: Icahn School of Medicine at Mount Sinai, Neurotrope Bioscience
    Inventors: Yiannis A. Ioannou, Lawrence Altstiel, David R. Crockford, Sathapana Kongsamut
  • Patent number: 9724349
    Abstract: Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: August 8, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Jun Chen, Joseph J. Buggy, Laurence Elias
  • Patent number: 9707236
    Abstract: Disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I: or a pharmaceutically acceptable salt thereof; in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer and may not respond to either agent administered as a sole therapy. The subject who has the cancer may also be refractory to at least one chemotherapy treatment, or is in relapse after treatment with chemotherapy, or both. The cancer may be a hematologic malignancy, such as leukemia or lymphoma, or a solid tumor cancer, such as pancreatic, lung and colon cancer.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: July 18, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Julie Di Paolo, Astrid Clarke
  • Patent number: 9694021
    Abstract: The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP).
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: July 4, 2017
    Assignee: ALCON RESEARCH, LTD
    Inventors: Masood A. Chowhan, Wesley Wehsin Han, L. Wayne Schneider
  • Patent number: 9687469
    Abstract: A pharmaceutical composition for the prevention and treatment of cancer with specific flavanoid-based compounds selected from among the groups of Flavone, Flavanone and Flavanol, a method for the prevention and treatment of cancer and inflammation using the specific flavonoid-based pharmaceutical compositions, a method for isolating the flavonoid-based pharmaceutical compositions from raw plant material, and a method for synthesizing said specific flavonoid-based pharmaceutical compositions.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: June 27, 2017
    Assignees: University of Maryland, Baltimore, Educational & Scientific LLC
    Inventors: Henry Lowe, Ngeh J. Toyang, Joseph Bryant